ARROWHEAD PHARMACEUTICALS, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 21.76 USD | -2.07% |
|
-8.69% | -28.89% |
| 09-03 | Sector Update: Health Care Stocks Lean Lower Pre-Bell Tuesday | MT |
| 09-03 | Transcript : Arrowhead Pharmaceuticals, Inc. - Shareholder/Analyst Call |
Company Valuation: Arrowhead Pharmaceuticals, Inc.
| Fiscal Period: September | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,686 | 4,405 | 6,509 | 3,498 | 2,880 | 2,705 | - | - |
| Change | - | 64.01% | 47.77% | -46.25% | -17.67% | -6.08% | - | - |
| Enterprise Value (EV) 1 | 2,686 | 4,089 | 6,141 | 3,390 | 2,769 | 2,522 | 2,805 | 2,992 |
| Change | - | 52.26% | 50.18% | -44.79% | -18.31% | -8.92% | 11.22% | 6.66% |
| P/E ratio | 40.8x | -51.3x | -45.9x | -19.8x | -14x | -4.82x | -5.35x | -6.16x |
| PBR | - | - | 15.9x | 8.79x | 10.6x | 20.7x | -22.4x | -17.7x |
| PEG | - | 0x | -0.7x | -0.9x | -0.9x | -0x | 0.54x | 0.5x |
| Capitalization / Revenue | 15.9x | 50.1x | 47.1x | 14.4x | 12x | 43.9x | 18x | 11.7x |
| EV / Revenue | 15.9x | 46.5x | 44.4x | 13.9x | 11.5x | 40.9x | 18.6x | 13x |
| EV / EBITDA | - | -46.9x | -43.6x | -20.2x | -14.4x | -4.71x | -5.15x | -5.75x |
| EV / EBIT | 43.9x | -43.9x | -41.2x | -19x | -13.5x | -4.52x | -5.13x | -5.97x |
| EV / FCF | 16.7x | -38.1x | 41.6x | -17.9x | -8.38x | -4.09x | -6.32x | -5.48x |
| FCF Yield | 6% | -2.63% | 2.4% | -5.57% | -11.9% | -24.5% | -15.8% | -18.3% |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | 0.69 | -0.84 | -1.36 | -1.67 | -1.92 | -4.519 | -4.071 | -3.531 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | 168.8 | 87.99 | 138.3 | 243.2 | 240.7 | 61.6 | 150.6 | 230.6 |
| EBITDA 1 | - | -87.22 | -140.8 | -168.1 | -192.5 | -535.9 | -544.3 | -520.5 |
| EBIT 1 | 61.19 | -93.16 | -149 | -178.5 | -205 | -558.2 | -547.1 | -500.9 |
| Net income 1 | 67.97 | -84.55 | -140.8 | -176.1 | -205.3 | -536.6 | -504.3 | -455.8 |
| Net Debt 1 | - | -315.5 | -367.8 | -108 | -110.9 | -182.9 | 100.1 | 287 |
| Reference price 2 | 28.18 | 43.06 | 62.43 | 33.05 | 26.87 | 21.76 | 21.76 | 21.76 |
| Nbr of stocks (in thousands) | 95,301 | 102,292 | 104,259 | 105,849 | 107,193 | 124,315 | - | - |
| Announcement Date | 25/11/19 | 23/11/20 | 22/11/21 | 28/11/22 | 29/11/23 | - | - | - |
1USD in Million2USD
Estimates
P/E ratio, Detailed evolution
| P/E ratio | EV / Sales | EV / EBITDA | Yield (Y) | Capi. ($) | ||
|---|---|---|---|---|---|---|
| -4.82x | 40.94x | -4.71x | -.--% | 2.71B | ||
| 30.77x | 8.08x | 19.69x | -.--% | 124B | ||
| -237.72x | 10.39x | 136.77x | -.--% | 122B | ||
| -541.56x | 14.9x | -181.09x | -.--% | 32.94B | ||
| -41.18x | 3.33x | -9.59x | -.--% | 23.9B | ||
| -31.74x | 5.2x | -31.98x | -.--% | 20.54B | ||
| 22.48x | 4.48x | 14.67x | -.--% | 17.42B | ||
| 12x | 2.61x | 7.41x | +2.45% | 15.77B | ||
| -26.56x | - | - | -.--% | 14.26B | ||
| 70.87x | 6.51x | 80.19x | -.--% | 12.18B | ||
| Average | -74.75x | 10.72x | 3.48x | +0.24% | 38.49B | |
| Weighted average by Cap. | -113.09x | 8.76x | 36.56x | +0.10% |
Year-on-year evolution of the PER
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Equities
- ARWR Stock
- Valuation Arrowhead Pharmaceuticals, Inc.
MarketScreener is also available in this country: United States.
Switch edition
Stay in the current country edition